https://www.selleckchem.com/Bcl-2.html
The primary outcomes are cessation of cannabis use (self-reported) and psychotic symptom severity. The secondary outcomes include frequency and quantity of cannabis use, global illness severity, psychosocial functioning, subjective well-being, cognition, sleep, circadian rhythmicity, and metabolomics. The results of this trial can potentially contribute with a new treatment paradigm for patients suffering from dual diagnosis. ClinicalTrials.gov , NCT04105231 , registered April 23rd, 2021. ClinicalTrials.gov , NCT04105231 , registered April 23rd, 2
Like
Comment
Share
